Company News

Latest News

Polaris Group's Affiliate Nanotein Technologies Launches a Revolutionary NK Cell Activation and Expansion Reagent
TAIPEI, Taiwan and VACAVILLE, Calif., June 07, 2023— Polaris Group (TWSE: 6550), a multinational biopharmaceutical...
Read more »
Polaris Group Presents Positive Phase 2/3 data for ADI-PEG 20, First-in-Class Arginine Depletion therapy in Patients with Malignant Pleural Mesothelioma at AACR Annual Meeting 2023
TAIPEI, Taiwan and SAN DIEGO, Calif., April 16, 2023 — Polaris Group (TWSE: 6550), a multinational biopharmaceutical...
Read more »
Polaris Group Announces Positive Top-Line Results from Phase 2/3 ATOMIC study in Patients with Malignant Pleural Mesothelioma to Assess ADI-PEG 20 with Pemetrexed and Cisplatin
TAIPEI, Taiwan and SAN DIEGO, Calif., September 21, 2022 — Polaris Group (TWSE: 6550), a multinational...
Read more »
Polaris Group Announces its listing on the Taiwan Stock Exchange on June 6, 2022
TAIPEI, Taiwan and SAN DIEGO, Calif., June 6, 2022 – Polaris Group (“Polaris”) (TWSE: 6550), a multinational...
Read more »
Polris Group received approval from the Listing Review Committee of Taiwan Stock Exchange for Primary Listing
The Taiwan Stock Exchange convened its 755th “Listing Review Committee for Securities” on March 4, 2022,...
Read more »
Polaris Pharmaceuticals steps into mRNA technology and actively integrates macromolecular pharmaceutical technology
Polaris, a multinational biotechnology company, has signed a corporate research sponsorship agreement...
Read more »
1 2 3 4 5 6
Scroll to Top
This site is registered on wpml.org as a development site.